Skip to content
Ono Pharma
-
Ono Pharmaceutical partners with Aitia to advance causal AI in neurological drug discovery
The approach is intended to support drug discovery in neurology, where diseases often arise from complex interactions involving genetic, developmental, neural network, immune and environmental factors.
-
Mediar Therapeutics collaborates with Ono Pharma on fibro-inflammatory antibody therapies
Under the agreement, Ono will work with Mediar to identify potential treatments using the biotechnology company’s fibrosis-focused discovery platform and expertise in myofibroblast biology and fibrosis-related pathways.